VRTX R&D to Revenue
Vertex Pharmaceuticals · R&D to Revenue
VRTX R&D to Revenue
Latest reported31.09%period ending
VRTX FY R&D/Revenue (0.00% → 31.09%)
Latest values, visible window
High-resolution chart · PNG
VRTX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 31.0876% | |
| 32.9425% | |
| 32.0482% | |
| 29.7379% | |
| 40.2817% | |
| 29.4816% | |
| 42.1479% | |
| 46.4785% | |
| 53.2266% | |
| 61.55% | |
| 96.4967% | |
| 147.3956% | |
| 75.8087% | |
| 52.7939% | |
| 50.1696% | |
| 444.5951% | |
| 539.628% | |
| 294.1768% | |
| 257.8005% | |
| 171.8062% | |
| 154.4782% | |
| 187.0791% | |
| 288.7375% | |
| 126.0316% | |
| 88.7653% | |
| 108.6961% | |
| 117.2078% | |
| 132.2072% | |
| 117.8082% | |
| 264.6617% | |
| 187.7828% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |